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Abstract
Recent studies have demonstrated growth-inhibiting effects of growth differentiation factor-15
(GDF-15) on different cancer cell lines invitro and on tumor growth in vivo. Here, we present data
concerning expression of GDF-15 in glioblastoma. We found low levels of GDF-15 transcripts in
primary glioblastoma. Thus, GDF-15 expression might be exploited as a useful indicator for
distinguishing primary from other glial derived tumors. In contrast to the documented proapoptotic and
anti-tumorigenic activities of GDF-15 in several cancer cell lines, our data suggest that GDF-15 does not
decrease proliferation of glioblastoma cell lines, while its effects on invasiveness are not consistent.
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Reviewer 1
1. First this subtitle "GDF-15 is differentially expressed in cultures of primary and secondary glioblastoma" is 
misleading.
We changed the subtitle into “Low expression of GDF-15 in cultures of primary glioblastomas” and present 
in the subsequent chapter data on diffuse astrocytomas grade II, anaplastic astrocytomas grade III, 
secondary glioblastomas grade IV, primary glioblastomas grade IV, oligodendroglioblastomas grade II and 
III, and oligoastrocytomas grade II and III.
We also changed the first subtitle of the Results part into “GDF-15 immunoreactivity in de novo glioblastoma, 
high grade astrocytoma and secondary glioblastoma” and subdivided figure 1 into A and B for the sake of 
clarity of the immunohistochemical results.
2. No details are given about how these cultures were derived, maintained or what passage numbers were 
used in the present studies.
Details are now provided in the Materials and Methods section on how the cultures were derived. 
Furthermore, data on GDF-15 expression in oligodendrogliomas grade II and III and oligoastrocytomas 
grade II and III were added to figure 2 and Results. We also incorporated a table comprising tumor type, 
passage numbers, age and sex of each specimen (Tab.1).
4. Did the authors conduct similar studies on the primary cell lines used in Figure 2?
Figure 2 shows real-time PCR results with cDNA of 59 different primary cell cultures with low passage 
numbers provided by the Molecular Biology Laboratories, Department of Neurosurgery, University of 
Heidelberg. Since cell cultures with similarly low passage numbers were not available we did not perform 
invasion-, proliferation-, and TUNEL-assays on primary cell lines. 
5. How do the authors explain the differences in responsiveness of the different cell lines?
Our studies show that the GDF-15 antiserum decreases proliferation in 8 of 9 cell cultures. Exogenous GDF-
15 increased cell division in 4 cell lines, while the remaining 5 cell lines did not respond. Several possibilities 
may be conceived to explain this result. First, cell lines unresponsive to exogenous GDF-15, but responsive 
to the anti-GDF-15 might already be maximally stimulated by the endogenous GDF-15. Moreover, non-
responsive cell lines might require, in addition to GDF-15, a synergistically acting factor, which was not 
available at the required amounts. Alternatively, GDF-15 receptors in non-responsive cell lines might already 
be maximally saturated with endogenous GDF-15. A similar explanation might account for the lack of 
response to exogenous GDF-15 in the invasion experiments. It should be noted, however, that both U87MG 
and, to a lesser extent, LN-428 and LN-229, showed a tendency to respond to GDF-15. 
It has been shown that, dependent on tumor type and origin (for review see Eling at al., 2006; Bauskin et al., 
2006), GDF-15 can exhibit either tumorigenic or anti-tumorigenic activity. The cell lines investigated in our 
studies are derived from tumors of different stages and origin, and it is therefore conceivable that GDF-15 
may regulate in either a positive or negative manner, depending on molecular and cellular contexts. 
Antagonistic effects have also been shown for TGF  and its effects on different glioma cell lines (see also 
Jennings et al., 1991). 
Although previous studies suggested that GDF-15 can regulate invasiveness in cancer cell lines, results of 
these former studies were based on a single cell line, without comparing the results with other cell lines 
derived from the same cancer types. It has been shown, for example, that GDF-15 significantly increases 
invasiveness of SNU-216, a human gastric cancer cell line (Lee et al., 2003). Evidently, this does not prove 
that all available gastric cancer cell lines would respond in the same way. Our study compares GDF-15 
dependent invasion in 8 different cancer cell lines, which may differ in a variety of subtle respects. 
6. Lastly, no effect on apoptosis was noted. How do the authors explain this result, which is different from 
previously published studies?
Most in vitro studies suggest GDF-15- induces apoptosis in cancer cell lines. However, data from the 
literature provide high expression of GDF-15 in many tumors, a finding that is hard to be reconciled with the 
proposed tumor suppressor activity of GDF-15. Previous studies from our laboratory clearly demonstrate 
that GDF-15 can protect cerebellar granule cells from apoptotic cell death in vitro (Subramaniam et al., 
2003), i.e. GDF-15 may function as an anti-apoptotic factor. To our knowledge, none of the previously 
published studies has shown pro-apoptotic effects of GDF-15 in glioma cultures.  
7. The conclusions of this study are overstated.
Conclusions have been changed 
Reviewer 2
1. How are primary and secondary GBM differentiated (clinically or molecular). 
Primary and secondary GBM were differentiated as described earlier [22] In brief, tumors were 
histopathologically classified according to the classification of the WHO. Tumors were characterized as 
secondary GBM in patients with previous identified low grade (WHO II and WHO III) glioblastomas in 
accordance with Kleihues. 
  
2. Why was no fresh material used for qPCR?
We have now included fresh material provided by the Molecular Biology Laboratories, Department of 
Neurosurgery, University of Heidelberg. We got 9 frozen tissue samples of primary GBM and used the 
samples for qPCR and immunohistochemistry. The results of the qPCR with fresh primary GBM confirmed 
data obtained by IHC (low GDF-15 expression in 8 out of 9 tumors, (see also the figure on the last page of 
our revision notes). Three of the primary cultures used for qPCR correspond to fresh tissue samples (Tab.1). 
Since one secondary GBM, two anaplastic astrocytoma and one oligodendroblastoma were provided as 
frozen sections on coverslips we could not perform qPCR and used the material directly for 
immunohistochemistry. However, primary cells derived from these tumors revealed high amounts of GDF-15 
mRNA (Tab.1), although we were not able to show any ir in the oligodendroglioma grade III. 
3. What is a low-passage culture and how was the immunohisto / qPCR correlation?
We added a list with tumor number, passage number, sex and age of the total material used in this study 
(Tab. 1).
4. Table 2 should be presented earlier in the results section.
The correlation of p53 and GDF-15 is now mentioned in the Results section.
5. Discussion should be shortened.
We now shortened the discussion.      
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Recent studies have demonstrated growth-inhibiting effects of Growth differentiation factor-
15 (GDF-15) on different cancer cell lines in vitro and on tumor growth in vivo. Here, we 
present data concerning expression of GDF-15 in glioblastoma. We found low levels of GDF-
15 transcripts in primary glioblastoma. Thus, GDF-15 expression might be exploited as a 
useful indicator for distinguishing primary from other glial derived tumors. In contrast to the 
documented proapoptotic and anti-tumorigenic activities of GDF-15 in several cancer cell 
lines, our data suggest that GDF-15 does not decrease proliferation of glioblastoma cell lines, 
while its effects on invasiveness are not consistent.
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3Introduction
Growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 
[1], prostate-derived factor [2], placental bone morphogenetic protein [3], and nonsteroidal 
anti-inflammatory drug-activated protein-1 [4], is a divergent member of the TGF-ß 
superfamily and widely expressed in epithelial tissues and in brain [5, 6, 7]. 
Most recently, several reports have provided evidence for functional links between GDF-15 
and factors involved in tumorigenesis. The tumor suppressor gene product p53, for instance, 
strongly induces GDF-15, indicating for the first time a functional connection between p53 
and the TGF-ß superfamily [8-12]. Nonsteroidal anti-inflammatory drugs (NSAIDs) that 
inhibit tumor development can also increase GDF-15 expression [13]. Other studies have 
documented increased levels of GDF-15 in serum and in tumors of patients with metastatic 
cancer [14-18]. Perhaps most excitingly, GDF-15 has been reported to exert proapoptotic and 
anti-tumorigenic functions on human colorectal, prostate, breast, and mammary cancer cells 
in vitro and on colon and glioblastoma tumors in vivo [4, 8, 19-21]. Together, these findings 
strongly suggest a putative role of GDF-15 in tumor development and/or progression and 
underscore the importance of further exploration of an involvement of GDF-15 in 
tumorigenesis.
We report here the expression of GDF-15 in human glioblastoma tissues, glioblastoma 
primary cultures, and glioblastoma cell lines. Our analyses reveal that GDF-15 may be 
implicated in the regulation of proliferation and invasiveness of human glioblastoma cells.
4Materials and Methods
Samples and Cell culture 
Tissue specimens were obtained intraoperatively from central parts of the tumors. Primary 
and secondary GBM were histopathologically classified according to the classification of the 
WHO. Tumors were characterized as secondary GBM in patients with previous identified low 
grade (WHO II and WHO III) glioblastomas. Primary cultures of glioma tissues (Tab. 1) were 
established as described earlier [22]. The human glioma cell lines A172, D247MG, LN-18, 
LN-229, LN-308, LN-319, and LN-428 (see Tab. 2) were maintained in DMEM with 4.5 g 
glucose/L supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin. 
Cultures were maintained in a humidified 5% CO2 atmosphere at 37
oC. 
GDF-15 immunohistochemistry
Samples of primary and secondary glioblastomas were obtained from surgical cases in the 
Department of Neurosurgery, University of Heidelberg, Germany. Snap frozen samples were 
embedded in Tissue-Tek (Sakura, Ramsey, MI, USA) and directly cut  into 16µm slices. For 
immunohistochemistry, sections were fixed in 4% PFA for 1 hour. Non-specific peroxidase 
activity was blocked by incubating sections in 1% hydrogen peroxide in PBS for 10 min at 
room temperature (RT). Non-specific antibody binding was blocked using blocking buffer 
(5% goat serum and 0.1% Triton X-100 in PBS) for 1 hour at RT. After washing, coverslips 
were incubated with rabbit anti-mouse GDF-15 polyclonal antibodies (affinity-purified and 
diluted 1:200) or with PBS overnight at 4oC. Slides were subsequently washed 3 times for 5 
min in PBS and incubated 30 min at RT with biotinylated goat anti-rabbit IgG (Vectastain 
Elite ABC Kit, Vector Laboratories, Burlingame, CA, USA). All subsequent steps were 
performed according to the manufacturer’s instructions. Slides were counterstained with 
hematoxylin, coverslipped, and photographed using a Zeiss Axioplan 2 equipped with 
5AxioVision 3.1 software. Immunofluorescence was performed as described [23]. Primary 
antibodies used were affinity purified polyclonal anti-GDF-15, monoclonal anti-CD68 (BD 
Biosciences, San Jose, CA, USA), and monoclonal anti-GFAP (Sigma, Chicago, IL, USA). 
Secondary antibodies were anti-mouse IgG Cy2 and anti-rabbit IgG Cy3 (Jackson 
ImmunoResearch, West Baltimore Pike West Grove, PA, USA)
Gel electrophoresis and immunoblot analyses
Protein extracts were prepared by homogenizing the cells in electrophoresis sample buffer, 
and the protein content was determined using densitometry [24]. 25µg protein extract per lane 
were loaded on SDS-polyacrylamide gels and transferred to nitrocellulose membranes 
(Hybond ECL, Amersham Pharmacia, Göttingen, Germany) by electroblotting. The 
membranes were incubated with purified polyclonal rabbit anti-rat GDF-15/MIC-1 antibody 
for 16 h at 4 °C. Bound antibody was detected with a peroxidase-conjugated secondary 
antibody and the ECL western blotting substrate system (Amersham Pharmacia) according to 
the manufacturer´s manual. Samples of purified recombinant GDF-15 were visualized with 
Coomassie blue and quantified by densitometry comparison [24] with defined concentrations 
of protein standards.
ELISA
For the determination of secreted GDF-15 from the glioma cell lines, 25.000 cells/well were 
seeded in 48 well plates. The cell culture supernatants were collected after 24 hours and the 
amount of GDF-15 determined by sandwich ELISA using a monoclonal anti-human GDF-15 
capture antibody (R&D Systems, MAB957) and a biotinylated goat anti-human GDF-15 
detection antibody (R&D Systems, BAF940) according to the manufacturer’s protocol. 
Recombinant human GDF-15 (R&D Systems) diluted in medium (15 pg/ml to 250 pg/ml) 
6was used as a standard for the determination of the total amount of GDF-15 secreted by the 
cells. The number of cells per well after 14 hours was determined by direct counting. The 
experiment was performed three times with every cell line tested in triplicate per experiment. 
Total RNA extraction and cDNA synthesis
Samples of tumor tissue (100 – 200 mg each) and cultured glioma cells were lysed in 
peqGOLD TriFast reagent (Peqlab, Erlangen, Germany), and phenol-chloroform extraction of 
total RNA was performed. Prior to reverse transcription RNA samples were treated with RQ1 
DNase (Promega). cDNA synthesis was then performed using M-MLV Reverse Transcriptase 
(Promega). Additionally, total RNA was extracted from primary (low-passage) cultures 
established from glioma tissue of different malignancy grades.
Real-time quantitative RT-PCR analysis
Relative quantitation of human GDF-15 and GAPDH transcripts in cDNA samples was 
performed on an ABI PRISM 7000 Sequence Detection System using the corresponding 
TaqMan Assays-on-Demand Gene Expression Products (Applied Biosystems) and following 
the manufacturer’s protocol. Each sample was analyzed in triplicate. GAPDH expression was 
considered as an internal control to which GDF-15 expression was normalized.
Cell proliferation assays
Cells were seeded onto 96-well plates at a density of 104 (for U373MG: 5 x 103) cells/well. 
On the next day, cultures were treated with rabbit anti-mouse GDF-15 polyclonal serum (5 
L/ml), pre-immune serum (5 l/ml) as a control, or human recombinant GDF-15 (20 ng/ml) 
(R&D). 24 hours later, cell proliferation was measured using 5-Bromo-2`-deoxy-uridine 
7labeling and the Detection Kit III (Roche Applied Science), following the manufacturer’s 
instructions.
In vitro cell invasion assays
The ability of cells to migrate through Matrigel-coated filters was determined using the 24-
well plate BD BioCoat Matrigel Invasion Chamber (BD Biosciences, Bedford, MA, USA).
Briefly, cells were seeded at a density of 2.5x104 cells in 500 L DMEM onto Matrigel 
inserts. Rabbit anti-mouse GDF-15 polyclonal serum (5 l/m), pre-immune serum (5 l/ml, as 
a control), or human recombinant GDF-15 (20 ng/ml) were added to the inserts. Wells of the 
24-well plates contained DMEM supplemented with 5% FBS as a chemoattractant. After 
incubation for 24 h at 37oC in 5% CO2 the cells that had not invaded the filters were removed 
with cotton swabs, and cells that had migrated to the lower surface of the filter were fixed in 
methanol. Cells were then stained with Toluidine Blue (Merck, Darmstadt, Germany) and 
counted in 32 fields (x200) per filter, covering the periphery and the center of the membrane. 
All experiments were performed in triplicate.
TUNEL
Cells were washed and fixed with 4% PFA, permeabilized with 0.2% Triton X-100, and 
processed for TUNEL (Promega). 5 µg/ml DAPI was added to stain cell nuclei. 
Photomicrographs from 4-6 different fields in each coverslip were captured under green 
channels and merged using adobe photoshop 5.5. Typically, about 1000 cells were analyzed 
for the number of TUNEL-positive glioblastoma cells.
8Statistical analysis
Data were expressed as means ± SEM. All experiments were performed in triplicates or 
duplicates and repeated at least three times. Statistical analyses among groups were performed 
using the t test (Origin 6.1). P-values are as follows: * P < 0.05, ** P < 0.01, and *** P < 
0.001. 
9Results
GDF-15 immunoreactivity in de novo glioblastoma, high grade astrocytoma and 
secondary glioblastoma
We first investigated the possible presence of GDF-15 protein in surgically removed human 
primary and secondary glioblastomas using immunohistochemistry. Only one out of the nine 
investigated primary glioblastomas grade IV showed moderate GDF-15 immunoreactivity (ir)
(Figure 1A; left panel). GDF-15 staining was localized to tumor cells, but absent from blood 
vessels. The right panel shows the control experiment where the GDF-15 antibody was
omitted. In contrast to the largely GDF-15 negative primary glioblastomas we found 
prominent staining for GDF-15 ir in 2 anaplastic astrocytomas grade III (AAG III) and one
secondary glioblastoma. The upper left panel of Figure 1B exemplifies GDF-15 ir in one of 
the AAG III. Notably, the stroma and perivascular spaces of the AAG III were 
immunoreactive for GDF-15. An oligodendroglioma grade III (OG III) was negative for 
GDF-15 ir. In samples of tumor tissues, where GDF-15 ir was detectable, there was no 
costaining of GDF-15 with glial fibrillary acidic protein (GFAP; Figure 1B; bottom left 
panel). Similarly, GDF-15 immunoreactive cells in AAG III (Figure 1B; bottom right panel)
and secondary glioblastomas did not show co-labeling for the microglial marker CD68.
Together, these data suggest the presence of GDF-15 protein in GFAP- and CD68-negative 
cells, preferentially in AAG III and secondary glioblastoma.
Lowest expression of GDF-15 in cultures of primary glioblastomas 
Diffuse astrocytomas grade II (DAG II), anaplastic astrocytomas grade III (AAG III), and 
secondary glioblastomas grade IV (SGG IV) represent distinct stages in the evolution of 
secondary glioblastomas, whereas primary glioblastomas grade IV (PGG IV) develop along a 
different genetic pathway [25]. Other brain tumours distinguishable from those mentioned 
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above due to their distinct genetical alteration, mainly characterized by a combined loss of 
chromosomes 1p and 19q, are oligodendroglioblastomas and oligoastrocytomas grade II and
III (OGG II, OGG III; OAG II, OAG III) [26,27]. Figure 2 shows the results of quantitative 
real-time PCR determinations of GDF-15 mRNA expressed in cultures derived from 8 DAG 
II, 8 AAG III, 8 SGG IV, 8 PGG IV, 5 OGG II, 5 OGG III, 5 OAG II, and 5 OAG III. High 
and largely comparable expression levels were found in DAG II, AAG III, and SGG IV
(Figure 2). In contrast, PGG IV showed significantly lower levels of GDF-15 expression. This 
difference was even more pronounced when GDF-15 expression in PGG IV was compared to 
the average expression levels of cell cultures derived from oligodendroglioblastomas grade II 
(OGG II) and anaplastic oligodendroglioblastomas grade III (OGG III). The most frequent 
type of mixed glioblastomas, OAG II, also showed a significantly higher GDF-15 level 
compared to PGG IV. Thus, differences in GDF-15 expression might be exploited as a useful 
indicator for distinguishing primary from other glial derived tumors. 
GDF-15 expression does not correlate with spontaneous proliferation or the p53 status 
of glioma cell lines
In an attempt to elucidate putative functions of GDF-15 on glioblastoma growth we 
investigated a panel of 9 human glioma cell lines (LN-319, U87MG, A172, D-247MG, LN-
229, LN-308, LN-428, LN-18 and U373MG). We first compared the expression levels of 
endogenous GDF-15 mRNA in relation to the spontaneous proliferation rate for each human 
cell line. Figure 3A shows the wide range of mRNA expression levels in these cell lines, from 
very high rates in A172 and D-247MG cells to up to 15-fold lower levels in LN-18 and 
U87MG cells. Similar differences were found in terms of GDF-15 protein in cell lysates and 
supernatants of selected cell lines analysed by Western blot (Figure 3B) and ELISA assay 
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(Figure 3C). Rates of proliferation of the 9 cell lines varied up to 3-fold, but failed to 
correlate, neither in a positive or negative fashion, with levels of GDF-15 mRNA expression. 
Since several studies have reported a strong p53 dependent induction of GDF-15 in a large 
variety of cancers [4, 8-10], we additionally compared levels of GDF-15 expression with the 
p53 status of the cell lines. Highest GDF-15 mRNA expression was found in 3 cell lines with 
wt p53 status. However, p53 wt U87MG and mutant/p53 LN-18 cells showed lowest levels of 
GDF-15 transcripts (Fig. 3A, Tab. 2) suggesting no significant correlation between the p53 
status and the level of GDF-15 expression. 
GDF-15 modulates proliferation of glioma cell lines
We next analysed, whether endogenous GDF-15 has an effect on the proliferation of 
glioblastoma cells using a blocking antibody to GDF-15. As shown in Figure 4A, the antibody 
(5µl/ml) significantly attenuated the mitogenic activity of 8 of the 9 human glioblastoma cell 
lines. LN-18 cells showed no response to the antibody treatment in terms of proliferation.
Having shown that, with one exception, all glioblastoma cell lines employed in this study 
responded to endogenous GDF-15, we next investigated their responsiveness to exogenously 
applied GDF-15. As shown in Figure 4A, addition of recombinant GDF-15 (10ng/ml) to cell 
cultures promoted proliferation of A172, D-247MG, LN-18, LN-319, but had no effect on 
proliferation of LN-229, LN-308, LN-428, U373MG, and U373MG cells. 
Taken together, these data suggest that endogenous GDF-15 is implicated in promoting 
growth of most glioma cell lines studied, and that exogenous GDF-15 exerts growth 
promoting effects on a more restricted set of glioma cell lines. 
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GDF-15 modulates invasiveness of distinct glioma cell lines
Invasiveness is a key feature of glioblastoma cells [28]. Figure 4B reveals that neutralization 
of endogenous GDF-15 significantly suppressed invasiveness of LN-308 and U373MG
human glioma cells, promoted invasiveness of LN-428 cells, and did not affect invasiveness 
of the other cell lines studied. Exogenous GDF-15 did not interfere with invasiveness of any 
glioma cell line investigated. 
Together, these data indicate that endogenous, but not exogenous GDF-15 affects 
invasiveness of several but not all glioma cell lines studied.
GDF-15 does not affect apoptosis in glioma cell lines
Previous studies have identified GDF-15 as an important mediator of DNA damage in various 
cancer cell lines, explaining its largely anti-tumorigenic and proapoptotic effects [4, 8, 14]. To 
explore whether GDF-15 affects apoptosis in glioblastoma cell lines we quantified the number 
of TUNEL positive cells in cultures previously treated with recombinant GDF-15 or GDF-15 
antiserum (Table 3). Comparisons with control cultures showed no difference in numbers of 
TUNEL positive cells suggesting that neither exogenous GDF-15 nor the inhibition of 




The present study provides evidence for expression of GDF-15 in select human glioblastoma 
tissues, glioblastoma primary cultures, and glioblastoma cell lines. While GDF-15 
immunoreactivity was prominent in 3 of the 4 investigated secondary glioblastomas, only one 
of nine primary glioblastomas showed staining for GDF-15. In support of the notion that 
primary and secondary glioblastomas may differ with regard to their GDF-15 protein 
expression, quantitative real-time RT-PCR carried out on cultured primary and secondary 
glioblastoma cells revealed higher levels of GDF-15 transcripts in secondary as compared to 
primary glioblastoma cells. With regard to secondary glioblastoma cell cultures we found an 
overall high expression in all WHO grades, but no differences that could be correlated to the 
degree of malignancy. This suggests that GDF-15 is unlikely to hold a key position in terms 
of promoting progression of glioblastoma from a less to a more malignant phenotype 
It is well established that the genetic pathways of primary and secondary glioblastomas 
leading to glioma as the common phenotypic endpoint are different and show little overlap 
[29]. Thus, higher expression levels of GDF-15 mRNA in secondary than primary 
glioblastomas might be regulated by one or several of the known mutated, down- or 
upregulated signalling pathways. In this context, p53 mutations were among the first genetic 
alterations identified in glioma tumors. p53 mutations are less common in primary 
glioblastoma (< 10%), while secondary glioblastomas have a high incidence of p53 mutations 
(>65%). In the light of studies that have reported a strong p53 dependent induction of GDF-15 
in a large variety of cancers [4, 8-10], we had expected to detect lower levels of GDF-15 
expression in secondary glioblastoma because of increased probability for p53 mutations. One 
explanation for this somewhat unexpected result might be a possible p53 independent 
regulation of GDF-15 gene expression. p53 independent upregulation of GDF-15 has 
previously been shown as a result of DNA damage, induced by genotoxic agents, irradiation 
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[8], or treatments with nonsteroidal anti-inflammatory drugs [4]. Thus, it is likely that GDF-
15 can be regulated through signals and pathways not involving p53.
Immunocytochemistry carried out on primary and secondary glioblastoma tissues revealed 
clear differences in the localization of GDF-15 protein. In the primary glioblastoma GDF-15 
immunoreactivity was exclusively localized in tumor cells, but absent from blood vessels and 
perivascular areas. In contrast, we found prominent GDF-15 immunoreactivity in the ECM of 
perivascular spaces of 2 anaplastic astrocytoma grade III (AAG III) and one secondary 
glioblastoma grade IV (SGG IV), whereas tumor cells and microglia were GDF-15-negative. 
Thus, it appears that GDF-15 of secondary glioblastomas is primarily located in the ECM. 
Stromal ECM stores for GDF-15 in prostate tumors have previously been shown by Bauskin 
and co-workers [30]. Interestingly, increased stromal stores of GDF-15 in prostate tumors 
were associated with a significantly greater chance of remaining disease free. Whether 
stromal storage of proGDF-15 in the ECM has a biological significance in secondary 
glioblastomas remains to be elucidated. 
To address putative roles of GDF-15 for glioblastoma cell properties, we investigated GDF-
15 expression and functions in a panel of 9 human glioblastoma cell lines with different p53 
backgrounds. We found only weak GDF-15 mRNA expression in cell lines showing p53
mutations or deletions. Two of the four cell lines with wild type p53 status showed a higher 
GDF-15 expression rate. This difference was further reflected in the amount of GDF-15 
protein levels. Whether or not the increased expression depends on p53 remains to be 
investigated. 
Previous studies have identified GDF-15 as an important downstream mediator of DNA 
damage signalling in various cancer cell lines and anti-tumorigenic and proapoptotic effects 
of GDF-15 have been reported [4, 8, 16]. Moreover, recent reports demonstrated that 
transfection of GDF-15 cDNA into human colorectal carcinoma and glioblastoma cells 
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decreased tumor growth in vivo and in vitro [4, 19]. In the present study we were unable to 
demonstrate that recombinant GDF-15 activates apoptosis and/or suppresses proliferation of 
glioblastoma cell lines. Our analyses rather revealed that exogenously added GDF-15 has no 
effect or can stimulate proliferation of glioblastoma cell lines. More importantly, neutralizing 
antibodies against GDF-15 attenuated the mitogenic activity of 8 (out of nine) cell lines 
suggesting that blocking antibodies or Fab fragments of GDF-15 might be developed into a 
therapeutic tool for treating glioblastoma. Together, the present and previous sets of data do 
not allow to assign unequivocal promoting or inhibitory roles to GDF-15 in the regulation of 
cell proliferation.
GDF-15 ambiguously affected glioma cell invasiveness in this study. Other studies carried out 
with other types of cancer cells have shown that recombinant GDF-15 can promote 
invasiveness of gastric cancer cells in a dose dependent manner [31]. Similarly, loss of cell 
adhesion has been described in prostate cancer cells upon GDF-15 treatment [16]. Given the 
diversity of effects exerted by GDF-15 in relation to invasiveness depending on cancer cell 
type, it is conceivable that GDF-15, as other members of the TGF-ß superfamily, may 
function in a crucially context-dependent manner  
In conclusion, we have provided evidence for distinct levels and sites of expression of GDF-
15, a distant member of the TGF-ß superfamily, in primary and secondary glioblastoma. In 
contrast to the documented proapoptotic and anti-tumorigenic activities of GDF-15 in several 
cancer cell lines, our data suggest that GDF-15 does not decrease proliferation of
glioblastoma cell lines, while its effects on invasiveness are inconsistent. Mechanisms that 
determine the distinct directions of the effects of GDF-15 may be sought in its context-
dependent actions with other growth factors. 
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Fig. 1A. Presence of GDF-15 in human primary and secondary glioblastoma tissue samples. 
Left panel, peroxidase immunostaining of GDF-15 in a primary glioblastoma counterstained 
with hematoxylin. Tumor cells are GDF-15 positive (T), whereas no staining was detectable 
in the stroma of the tumor (S). Right panel, in the negative control (without 1st antibody), no 
unspecific binding was observed. Fig. 1B. Fluorescence immunostainings of GDF-15, CD68 
and GFAP in serial sections of an anaplastic astrocytoma grade III. Upper left panel 
represents an overlay of GDF-15 and DAPI staining. Notably, GDF-15 is present in the 
perivascular spaces of the stroma. Upper right panel: negative control using GDF-15 pre-
immune serum and DAPI staining. Bottom left panel: GFAP positive tumor cells are negative 
for GDF-15. Bottom right panel: CD68 positive microglia do not show GDF-15 
immunoreactivity. 
Fig. 2. GDF-15 expression in primary cultures from human brain tumors of different origin 
and malignancy grades was analyzed by quantitative RT-PCR. GDF-15 expression was 
normalized against GAPDH and ß-Actin. PGG IV showed a significantly lower GDF-15 
expression compared to SGG IV or OAG II (p<0.05). Comparison of PGG IV with OGG II or 
OGG III revealed a significant difference of p<0.01. DAG II: diffuse astrocytomas grade II; 
AAG III: anaplastic astrocytomas grade III; SGG IV: secondary glioblastomas grade IV; PGG 
IV: primary glioblastomas grade IV: oligodendroglioblastomas grade II and III; OGG II and 
III: oligoastrozytomas grade II and III; OAG II and III. Bars represent mean ± SD.
Fig. 3. No correlation exists between GDF-15 expression and rates of proliferation in 
glioblastoma cell lines. (A) The upper figure shows GDF-15 expression levels in nine human 
glioblastoma cell lines (quantitative RT-PCR), the lower figure shows proliferation rates of 
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the same cell lines, measured by BrdU incorporation. Bars represent ± SD. (B) Immunoblots 
of cell lysates with purified GDF-15 antiserum confirm the highest expression of GDF-15 
protein in D-247MG and A-172 cells. (C) GDF-15 protein concentrations per 10.000 cells in 
supernatants of D-247MG, LN-308 and U87MG using an ELISA assay.
Fig. 4. Effects of GDF-15 anti-serum and recombinant human GDF-15 on the rates of 
proliferation and invasive capacities of glioblastoma cell lines. (A) Proliferation assays 
performed on ten glioblastoma cell lines show that the growth of most cell lines is inhibited 
by GDF-15 anti-serum and slightly stimulated by recombinant GDF-15. (B) Invasion assays 
indicate that recombinant GDF-15 does not affect invasiveness of glioblastoma cell lines. 
However, GDF-15 anti-serum does significantly affect the invasive capacity of three of the 
glioblastoma cell lines. * p<0.05; ** p<0.01; *** p<0.001. Bars represent ± SD.
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2Abstract
Recent studies have demonstrated growth-inhibiting effects of Growth differentiation factor-
15 (GDF-15) on different cancer cell lines in vitro and on tumor growth in vivo. Here, we 
present data concerning expression of GDF-15 in glioblastoma. We found low levels of GDF-
15 transcripts in primary glioblastoma. Thus, GDF-15 expression might be exploited as a 
useful indicator for distinguishing primary from other glial derived tumors. In contrast to the 
documented proapoptotic and anti-tumorigenic activities of GDF-15 in several cancer cell 
lines, our data suggest that GDF-15 does not decrease proliferation of glioblastoma cell lines, 
while its effects on invasiveness are not consistent.
Key words: GDF-15, TGF- superfamily, glioblastomas, tumor 
3Introduction
Growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 
[1], prostate-derived factor [2], placental bone morphogenetic protein [3], and nonsteroidal 
anti-inflammatory drug-activated protein-1 [4], is a divergent member of the TGF-ß 
superfamily and widely expressed in epithelial tissues and in brain [5, 6, 7]. 
Most recently, several reports have provided evidence for functional links between GDF-15 
and factors involved in tumorigenesis. The tumor suppressor gene product p53, for instance, 
strongly induces GDF-15, indicating for the first time a functional connection between p53 
and the TGF-ß superfamily [8-12]. Nonsteroidal anti-inflammatory drugs (NSAIDs) that 
inhibit tumor development can also increase GDF-15 expression [13]. Other studies have 
documented increased levels of GDF-15 in serum and in tumors of patients with metastatic 
cancer [14-18]. Perhaps most excitingly, GDF-15 has been reported to exert proapoptotic and 
anti-tumorigenic functions on human colorectal, prostate, breast, and mammary cancer cells 
in vitro and on colon and glioblastoma tumors in vivo [4, 8, 19-21]. Together, these findings 
strongly suggest a putative role of GDF-15 in tumor development and/or progression and 
underscore the importance of further exploration of an involvement of GDF-15 in 
tumorigenesis.
We report here the expression of GDF-15 in human glioblastoma tissues, glioblastoma 
primary cultures, and glioblastoma cell lines. Our analyses reveal that GDF-15 may be 
implicated in the regulation of proliferation and invasiveness of human glioblastoma cells.
4Materials and Methods
Samples and Cell culture
Tissue specimens were obtained intraoperatively from central parts of the tumors. Primary 
and secondary GBM were histopathologically classified according to the classification of the 
WHO. Tumors were characterized as secondary GBM in patients with previous identified low 
grade (WHO II and WHO III) glioblastomas. Primary cultures of glioma tissues (Tab. 1) 
were established as described earlier [22]. The human glioma cell lines A172, D247MG, LN-
18, LN-229, LN-308, LN-319, and LN-428 (see Tab. 2) were maintained in DMEM with 4.5 
g glucose/L supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin. 
Cultures were maintained in a humidified 5% CO2 atmosphere at 37
oC.
GDF-15 immunohistochemistry
Samples of primary and secondary glioblastomas were obtained from surgical cases in the 
Department of Neurosurgery, University of Heidelberg, Germany. Snap frozen samples were 
embedded in Tissue-Tek (Sakura, Ramsey, MI, USA) and directly cut  into 16µm slices. For 
immunohistochemistry, sections were fixed in 4% PFA for 1 hour. Non-specific peroxidase 
activity was blocked by incubating sections in 1% hydrogen peroxide in PBS for 10 min at 
room temperature (RT). Non-specific antibody binding was blocked using blocking buffer 
(5% goat serum and 0.1% Triton X-100 in PBS) for 1 hour at RT. After washing, coverslips 
were incubated with rabbit anti-mouse GDF-15 polyclonal antibodies (affinity-purified and 
diluted 1:200) or with PBS overnight at 4oC. Slides were subsequently washed 3 times for 5 
min in PBS and incubated 30 min at RT with biotinylated goat anti-rabbit IgG (Vectastain 
Elite ABC Kit, Vector Laboratories, Burlingame, CA, USA). All subsequent steps were 
performed according to the manufacturer’s instructions. Slides were counterstained with 
hematoxylin, coverslipped, and photographed using a Zeiss Axioplan 2 equipped with 
5AxioVision 3.1 software. Immunofluorescence was performed as described [23]. Primary 
antibodies used were affinity purified polyclonal anti-GDF-15, monoclonal anti-CD68 (BD 
Biosciences, San Jose, CA, USA), and monoclonal anti-GFAP (Sigma, Chicago, IL, USA). 
Secondary antibodies were anti-mouse IgG Cy2 and anti-rabbit IgG Cy3 (Jackson 
ImmunoResearch, West Baltimore Pike West Grove, PA, USA)
Gel electrophoresis and immunoblot analyses
Protein extracts were prepared by homogenizing the cells in electrophoresis sample buffer, 
and the protein content was determined using densitometry [24]. 25µg protein extract per lane 
were loaded on SDS-polyacrylamide gels and transferred to nitrocellulose membranes 
(Hybond ECL, Amersham Pharmacia, Göttingen, Germany) by electroblotting. The 
membranes were incubated with purified polyclonal rabbit anti-rat GDF-15/MIC-1 antibody 
for 16 h at 4 °C. Bound antibody was detected with a peroxidase-conjugated secondary 
antibody and the ECL western blotting substrate system (Amersham Pharmacia) according to 
the manufacturer´s manual. Samples of purified recombinant GDF-15 were visualized with 
Coomassie blue and quantified by densitometry comparison [24] with defined concentrations 
of protein standards.
ELISA
For the determination of secreted GDF-15 from the glioma cell lines, 25.000 cells/well were 
seeded in 48 well plates. The cell culture supernatants were collected after 24 hours and the 
amount of GDF-15 determined by sandwich ELISA using a monoclonal anti-human GDF-15 
capture antibody (R&D Systems, MAB957) and a biotinylated goat anti-human GDF-15 
detection antibody (R&D Systems, BAF940) according to the manufacturer’s protocol. 
Recombinant human GDF-15 (R&D Systems) diluted in medium (15 pg/ml to 250 pg/ml) 
6was used as a standard for the determination of the total amount of GDF-15 secreted by the 
cells. The number of cells per well after 14 hours was determined by direct counting. The 
experiment was performed three times with every cell line tested in triplicate per experiment. 
Total RNA extraction and cDNA synthesis
Samples of tumor tissue (100 – 200 mg each) and cultured glioma cells were lysed in 
peqGOLD TriFast reagent (Peqlab, Erlangen, Germany), and phenol-chloroform extraction of 
total RNA was performed. Prior to reverse transcription RNA samples were treated with RQ1 
DNase (Promega). cDNA synthesis was then performed using M-MLV Reverse Transcriptase 
(Promega). Additionally, total RNA was extracted from primary (low-passage) cultures 
established from glioma tissue of different malignancy grades.
Real-time quantitative RT-PCR analysis
Relative quantitation of human GDF-15 and GAPDH transcripts in cDNA samples was 
performed on an ABI PRISM 7000 Sequence Detection System using the corresponding 
TaqMan Assays-on-Demand Gene Expression Products (Applied Biosystems) and following 
the manufacturer’s protocol. Each sample was analyzed in triplicate. GAPDH expression was 
considered as an internal control to which GDF-15 expression was normalized.
Cell proliferation assays
Cells were seeded onto 96-well plates at a density of 104 (for U373MG: 5 x 103) cells/well. 
On the next day, cultures were treated with rabbit anti-mouse GDF-15 polyclonal serum (5 
L/ml), pre-immune serum (5 l/ml) as a control, or human recombinant GDF-15 (20 ng/ml) 
(R&D). 24 hours later, cell proliferation was measured using 5-Bromo-2`-deoxy-uridine 
7labeling and the Detection Kit III (Roche Applied Science), following the manufacturer’s 
instructions.
In vitro cell invasion assays
The ability of cells to migrate through Matrigel-coated filters was determined using the 24-
well plate BD BioCoat Matrigel Invasion Chamber (BD Biosciences, Bedford, MA, USA).
Briefly, cells were seeded at a density of 2.5x104 cells in 500 L DMEM onto Matrigel 
inserts. Rabbit anti-mouse GDF-15 polyclonal serum (5 l/m), pre-immune serum (5 l/ml, as 
a control), or human recombinant GDF-15 (20 ng/ml) were added to the inserts. Wells of the 
24-well plates contained DMEM supplemented with 5% FBS as a chemoattractant. After 
incubation for 24 h at 37oC in 5% CO2 the cells that had not invaded the filters were removed 
with cotton swabs, and cells that had migrated to the lower surface of the filter were fixed in 
methanol. Cells were then stained with Toluidine Blue (Merck, Darmstadt, Germany) and 
counted in 32 fields (x200) per filter, covering the periphery and the center of the membrane. 
All experiments were performed in triplicate.
TUNEL
Cells were washed and fixed with 4% PFA, permeabilized with 0.2% Triton X-100, and 
processed for TUNEL (Promega). 5 µg/ml DAPI was added to stain cell nuclei. 
Photomicrographs from 4-6 different fields in each coverslip were captured under green 
channels and merged using adobe photoshop 5.5. Typically, about 1000 cells were analyzed 
for the number of TUNEL-positive glioblastoma cells.
8Statistical analysis
Data were expressed as means ± SEM. All experiments were performed in triplicates or 
duplicates and repeated at least three times. Statistical analyses among groups were performed 
using the t test (Origin 6.1). P-values are as follows: * P < 0.05, ** P < 0.01, and *** P < 
0.001. 
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GDF-15 immunoreactivity in de novo glioblastoma, high grade astrocytoma and 
secondary glioblastoma
We first investigated the possible presence of GDF-15 protein in surgically removed human 
primary and secondary glioblastomas using immunohistochemistry. Only one out of the nine 
investigated primary glioblastomas grade IV showed moderate GDF-15 immunoreactivity (ir)
(Figure 1A; left panel). GDF-15 staining was localized to tumor cells, but absent from blood 
vessels. The right panel shows the control experiment where the GDF-15 antibody was
omitted. In contrast to the largely GDF-15 negative primary glioblastomas we found 
prominent staining for GDF-15 ir in 2 anaplastic astrocytomas grade III (AAG III) and one
secondary glioblastoma. The upper left panel of Figure 1B exemplifies GDF-15 ir in one of 
the AAG III. Notably, the stroma and perivascular spaces of the AAG III were 
immunoreactive for GDF-15. An oligodendroglioma grade III (OG III) was negative for 
GDF-15 ir. In samples of tumor tissues, where GDF-15 ir was detectable, there was no 
costaining of GDF-15 with glial fibrillary acidic protein (GFAP; Figure 1B; bottom left 
panel). Similarly, GDF-15 immunoreactive cells in AAG III (Figure 1B; bottom right panel)
and secondary glioblastomas did not show co-labeling for the microglial marker CD68.
Together, these data suggest the presence of GDF-15 protein in GFAP- and CD68-negative 
cells, preferentially in AAG III and secondary glioblastoma.
Lowest expression of GDF-15 in cultures of primary glioblastomas 
Diffuse astrocytomas grade II (DAG II), anaplastic astrocytomas grade III (AAG III), and 
secondary glioblastomas grade IV (SGG IV) represent distinct stages in the evolution of 
secondary glioblastomas, whereas primary glioblastomas grade IV (PGG IV) develop along a 
different genetic pathway [25]. Other brain tumours distinguishable from those mentioned 
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above due to their distinct genetical alteration, mainly characterized by a combined loss of 
chromosomes 1p and 19q, are oligodendroglioblastomas and oligoastrocytomas grade II and 
III (OGG II, OGG III; OAG II, OAG III) [26,27]. Figure 2 shows the results of quantitative 
real-time PCR determinations of GDF-15 mRNA expressed in cultures derived from 10 DAG 
II, 10 AAG III, 10 SGG IV, 10 PGG IV, 5 OGG II, 5 OGG III, 5 OAG II, and 5 OAG III.
High and largely comparable expression levels were found in DAG II, AAG III, and SGG IV
(Figure 2). In contrast, PGG IV showed significantly lower levels of GDF-15 expression. This 
difference was even more pronounced when GDF-15 expression in PGG IV was compared to 
the average expression levels of cell cultures derived from oligodendroglioblastomas grade II 
(OGG II) and anaplastic oligodendroglioblastomas grade III (OGG III). The most frequent 
type of mixed glioblastomas, OAG II, also showed a significantly higher GDF-15 level 
compared to PGG IV. Thus, differences in GDF-15 expression might be exploited as a useful 
indicator for distinguishing primary from other glial derived tumors. 
GDF-15 expression does not correlate with spontaneous proliferation or the p53 status 
of glioma cell lines
In an attempt to elucidate putative functions of GDF-15 on glioblastoma growth we 
investigated a panel of 9 human glioma cell lines (LN-319, U87MG, A172, D-247MG, LN-
229, LN-308, LN-428, LN-18 and U373MG). We first compared the expression levels of 
endogenous GDF-15 mRNA in relation to the spontaneous proliferation rate for each human 
cell line. Figure 3A shows the wide range of mRNA expression levels in these cell lines, from 
very high rates in A172 and D-247MG cells to up to 15-fold lower levels in LN-18 and 
U87MG cells. Similar differences were found in terms of GDF-15 protein in cell lysates and 
supernatants of selected cell lines analysed by Western blot (Figure 3B) and ELISA assay 
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(Figure 3C). Rates of proliferation of the 9 cell lines varied up to 3-fold, but failed to 
correlate, neither in a positive or negative fashion, with levels of GDF-15 mRNA expression. 
Since several studies have reported a strong p53 dependent induction of GDF-15 in a large 
variety of cancers [4, 8-10], we additionally compared levels of GDF-15 expression with the 
p53 status of the cell lines. Highest GDF-15 mRNA expression was found in 3 cell lines with 
wt p53 status. However, p53 wt U87MG and mutant/p53 LN-18 cells showed lowest levels of 
GDF-15 transcripts (Fig. 3A, Tab. 2) suggesting no significant correlation between the p53 
status and the level of GDF-15 expression. 
GDF-15 modulates proliferation of glioma cell lines
(deleted text)
We next analysed, whether endogenous GDF-15 has an effect on the proliferation of 
glioblastoma cells using a blocking antibody to GDF-15. As shown in Figure 4A, the antibody 
(5µl/ml) significantly attenuated the mitogenic activity of 8 of the 9 human glioblastoma cell 
lines. LN-18 cells showed no response to the antibody treatment in terms of proliferation.
Having shown that, with one exception, all glioblastoma cell lines employed in this study 
responded to endogenous GDF-15, we next investigated their responsiveness to exogenously 
applied GDF-15. As shown in Figure 4A, addition of recombinant GDF-15 (10ng/ml) to cell 
cultures promoted proliferation of A172, D-247MG, LN-18, LN-319, but had no effect on 
proliferation of LN-229, LN-308, LN-428, U373MG, and U373MG cells. 
Taken together, these data suggest that endogenous GDF-15 is implicated in promoting 
growth of most glioma cell lines studied, and that exogenous GDF-15 exerts growth 
promoting effects on a more restricted set of glioma cell lines. 
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GDF-15 modulates invasiveness of distinct glioma cell lines
Invasiveness is a key feature of glioblastoma cells [28]. Figure 4B reveals that neutralization 
of endogenous GDF-15 significantly suppressed invasiveness of LN-308 and U373MG
human glioma cells, promoted invasiveness of LN-428 cells, and did not affect invasiveness 
of the other cell lines studied. Exogenous GDF-15 did not interfere with invasiveness of any 
glioma cell line investigated. 
Together, these data indicate that endogenous, but not exogenous GDF-15 affects 
invasiveness of several but not all glioma cell lines studied.
GDF-15 does not affect apoptosis in glioma cell lines
Previous studies have identified GDF-15 as an important mediator of DNA damage in various 
cancer cell lines, explaining its largely anti-tumorigenic and proapoptotic effects [4, 8, 14]. To 
explore whether GDF-15 affects apoptosis in glioblastoma cell lines we quantified the number 
of TUNEL positive cells in cultures previously treated with recombinant GDF-15 or GDF-15 
antiserum (Table 3). Comparisons with control cultures showed no difference in numbers of 
TUNEL positive cells suggesting that neither exogenous GDF-15 nor the inhibition of 




The present study provides evidence for expression of GDF-15 in select human glioblastoma 
tissues, glioblastoma primary cultures, and glioblastoma cell lines. While GDF-15 
immunoreactivity was prominent in 3 of the 4 investigated secondary glioblastomas, only one 
of nine primary glioblastomas showed staining for GDF-15. In support of the notion that 
primary and secondary glioblastomas may differ with regard to their GDF-15 protein 
expression, quantitative real-time RT-PCR carried out on cultured primary and secondary 
glioblastoma cells revealed higher levels of GDF-15 transcripts in secondary as compared to 
primary glioblastoma cells. With regard to secondary glioblastoma cell cultures we found an 
overall high expression in all WHO grades, but no differences that could be correlated to the 
degree of malignancy. This suggests that GDF-15 is unlikely to hold a key position in terms 
of promoting progression of glioblastoma from a less to a more malignant phenotype 
It is well established that the genetic pathways of primary and secondary glioblastomas 
leading to glioma as the common phenotypic endpoint are different and show little overlap 
[29]. Thus, higher expression levels of GDF-15 mRNA in secondary than primary 
glioblastomas might be regulated by one or several of the known mutated, down- or 
upregulated signalling pathways. In this context, p53 mutations were among the first genetic 
alterations identified in glioma tumors. p53 mutations are less common in primary 
glioblastoma (< 10%), while secondary glioblastomas have a high incidence of p53 mutations 
(>65%). In the light of studies that have reported a strong p53 dependent induction of GDF-15 
in a large variety of cancers [4, 8-10], we had expected to detect lower levels of GDF-15 
expression in secondary glioblastoma because of increased probability for p53 mutations. One 
explanation for this somewhat unexpected result might be a possible p53 independent 
regulation of GDF-15 gene expression. p53 independent upregulation of GDF-15 has 
previously been shown as a result of DNA damage, induced by genotoxic agents, irradiation 
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[8], or treatments with nonsteroidal anti-inflammatory drugs [4]. (deleted text) Thus, it is 
likely that GDF-15 can be regulated through signals and pathways not involving p53.
Immunocytochemistry carried out on primary and secondary glioblastoma tissues revealed 
clear differences in the localization of GDF-15 protein. In the primary glioblastoma GDF-15 
immunoreactivity was exclusively localized in tumor cells, but absent from blood vessels and 
perivascular areas. In contrast, we found prominent GDF-15 immunoreactivity in the ECM of 
perivascular spaces of 2 anaplastic astrocytoma grade III (AAG III) and one secondary 
glioblastoma grade IV (SGG IV), whereas tumor cells and microglia were GDF-15-negative. 
Thus, it appears that GDF-15 of secondary glioblastomas is primarily located in the ECM. 
Stromal ECM stores for GDF-15 in prostate tumors have previously been shown by Bauskin 
and co-workers [30]. Interestingly, increased stromal stores of GDF-15 in prostate tumors 
were associated with a significantly greater chance of remaining disease free. Whether 
stromal storage of proGDF-15 in the ECM has a biological significance in secondary 
glioblastomas remains to be elucidated. 
To address putative roles of GDF-15 for glioblastoma cell properties, we investigated GDF-
15 expression and functions in a panel of 9 human glioblastoma cell lines with different p53 
backgrounds. We found only weak GDF-15 mRNA expression in cell lines showing p53
mutations or deletions. Two of the four cell lines with wild type p53 status showed a higher 
GDF-15 expression rate. This difference was further reflected in the amount of GDF-15 
protein levels. Whether or not the increased expression depends on p53 remains to be 
investigated. 
Previous studies have identified GDF-15 as an important downstream mediator of DNA 
damage signalling in various cancer cell lines and anti-tumorigenic and proapoptotic effects 
of GDF-15 have been reported [4, 8, 16]. Moreover, recent reports demonstrated that 
transfection of GDF-15 cDNA into human colorectal carcinoma and glioblastoma cells 
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decreased tumor growth in vivo and in vitro [4, 19]. In the present study we were unable to 
demonstrate that recombinant GDF-15 activates apoptosis and/or suppresses proliferation of 
glioblastoma cell lines. Our analyses rather revealed that exogenously added GDF-15 has no 
effect or can stimulate proliferation of glioblastoma cell lines. More importantly, neutralizing 
antibodies against GDF-15 attenuated the mitogenic activity of 8 (out of nine) cell lines 
suggesting that blocking antibodies or Fab fragments of GDF-15 might be developed into a 
therapeutic tool for treating glioblastoma. Together, the present and previous sets of data do 
not allow to assign unequivocal promoting or inhibitory roles to GDF-15 in the regulation of 
cell proliferation.
GDF-15 ambiguously affected glioma cell invasiveness in this study. Other studies carried out 
with other types of cancer cells have shown that recombinant GDF-15 can promote 
invasiveness of gastric cancer cells in a dose dependent manner [31]. Similarly, loss of cell 
adhesion has been described in prostate cancer cells upon GDF-15 treatment [16]. Given the 
diversity of effects exerted by GDF-15 in relation to invasiveness depending on cancer cell 
type, it is conceivable that GDF-15, as other members of the TGF-ß superfamily, may 
function in a crucially context-dependent manner  
In conclusion, we have provided evidence for distinct levels and sites of expression of GDF-
15, a distant member of the TGF-ß superfamily, in primary and secondary glioblastoma. In 
contrast to the documented proapoptotic and anti-tumorigenic activities of GDF-15 in several 
cancer cell lines, our data suggest that GDF-15 does not decrease proliferation of
glioblastoma cell lines, while its effects on invasiveness are inconsistent. Mechanisms that 
determine the distinct directions of the effects of GDF-15 may be sought in its context-
dependent actions with other growth factors. 
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Fig. 1A. Presence of GDF-15 in human primary and secondary glioblastoma tissue samples. 
Left panel, peroxidase immunostaining of GDF-15 in a primary glioblastoma counterstained 
with hematoxylin. Tumor cells are GDF-15 positive (T), whereas no staining was detectable 
in the stroma of the tumor (S). Right panel, in the negative control (without 1st antibody), no 
unspecific binding was observed. Fig. 1B. Fluorescence immunostainings of GDF-15, CD68 
and GFAP in serial sections of an anaplastic astrocytoma grade III. Upper left panel 
represents an overlay of GDF-15 and DAPI staining. Notably, GDF-15 is present in the 
perivascular spaces of the stroma. Upper right panel: negative control using GDF-15 pre-
immune serum and DAPI staining. Bottom left panel: GFAP positive tumor cells are negative 
for GDF-15. Bottom right panel: CD68 positive microglia do not show GDF-15 
immunoreactivity. 
Fig. 2. GDF-15 expression in primary cultures from human brain tumors of different origin 
and malignancy grades was analyzed by quantitative RT-PCR. GDF-15 expression was 
normalized against GAPDH and ß-Actin. PGG IV showed a significantly lower GDF-15 
expression compared to SGG IV or OAG II (p<0.05). Comparison of PGG IV with OGG II or 
OGG III revealed a significant difference of p<0.01. DAG II: diffuse astrocytomas grade II; 
AAG III: anaplastic astrocytomas grade III; SGG IV: secondary glioblastomas grade IV; PGG 
IV: primary glioblastomas grade IV: oligodendroglioblastomas grade II and III; OGG II and 
III: oligoastrozytomas grade II and III; OAG II and III. Bars represent mean ± SD.
Fig. 3. No correlation exists between GDF-15 expression and rates of proliferation in 
glioblastoma cell lines. (A) The upper figure shows GDF-15 expression levels in nine human 
glioblastoma cell lines (quantitative RT-PCR), the lower figure shows proliferation rates of 
21
the same cell lines, measured by BrdU incorporation. Bars represent ± SD. (B) Immunoblots 
of cell lysates with purified GDF-15 antiserum confirm the highest expression of GDF-15 
protein in D-247MG and A-172 cells. (C) GDF-15 protein concentrations per 10.000 cells in 
supernatants of D-247MG, LN-308 and U87MG using an ELISA assay.
Fig. 4. Effects of GDF-15 anti-serum and recombinant human GDF-15 on the rates of 
proliferation and invasive capacities of glioblastoma cell lines. (A) Proliferation assays 
performed on ten glioblastoma cell lines show that the growth of most cell lines is inhibited 
by GDF-15 anti-serum and slightly stimulated by recombinant GDF-15. (B) Invasion assays 
indicate that recombinant GDF-15 does not affect invasiveness of glioblastoma cell lines. 
However, GDF-15 anti-serum does significantly affect the invasive capacity of three of the 
glioblastoma cell lines. * p<0.05; ** p<0.01; *** p<0.001. Bars represent ± SD.
Dear Editor:
thank you very much for sending us the constructive criticisms of two reviewers on our 
manuscript. We have dealt with their remarks in every respect (see below) and now submit a 
carefully revised version of the paper. 
Response to Reviewers:
Reviewer 1
1. First this subtitle "GDF-15 is differentially expressed in cultures of primary and secondary 
glioblastoma" is misleading.
We changed the subtitle into “Low expression of GDF-15 in cultures of primary 
glioblastomas” and present in the subsequent chapter data on diffuse astrocytomas grade II, 
anaplastic astrocytomas grade III, secondary glioblastomas grade IV, primary glioblastomas 
grade IV, oligodendroglioblastomas grade II and III, and oligoastrocytomas grade II and III.
We also changed the first subtitle of the Results part into “GDF-15 immunoreactivity in de 
novo glioblastoma, high grade astrocytoma and secondary glioblastoma” and subdivided 
figure 1 into A and B for the sake of clarity of the immunohistochemical results.
2. No details are given about how these cultures were derived, maintained or what passage 
numbers were used in the present studies.
Details are now provided in the Materials and Methods section on how the cultures were 
derived. Furthermore, data on GDF-15 expression in oligodendrogliomas grade II and III and 
oligoastrocytomas grade II and III were added to figure 2 and Results. We also incorporated a 
table comprising tumor type, passage numbers, age and sex of each specimen (Tab.1).
4. Did the authors conduct similar studies on the primary cell lines used in Figure 2?
Figure 2 shows real-time PCR results with cDNA of 59 different primary cell cultures with 
low passage numbers provided by the Molecular Biology Laboratories, Department of 
Neurosurgery, University of Heidelberg. Since cell cultures with similarly low passage 
numbers were not available we did not perform invasion-, proliferation-, and TUNEL-assays 
on primary cell lines. 
5. How do the authors explain the differences in responsiveness of the different cell lines?
Our studies show that the GDF-15 antiserum decreases proliferation in 8 of 9 cell cultures. 
Exogenous GDF-15 increased cell division in 4 cell lines, while the remaining 5 cell lines did 
not respond. Several possibilities may be conceived to explain this result. First, cell lines 
unresponsive to exogenous GDF-15, but responsive to the anti-GDF-15 might already be 
maximally stimulated by the endogenous GDF-15. Moreover, non-responsive cell lines might 
require, in addition to GDF-15, a synergistically acting factor, which was not available at the 
required amounts. Alternatively, GDF-15 receptors in non-responsive cell lines might already 
be maximally saturated with endogenous GDF-15. A similar explanation might account for 
the lack of response to exogenous GDF-15 in the invasion experiments. It should be noted, 
however, that both U87MG and, to a lesser extent, LN-428 and LN-229, showed a tendency 
to respond to GDF-15. 
It has been shown that, dependent on tumor type and origin (for review see Eling at al., 2006; 
Bauskin et al., 2006), GDF-15 can exhibit either tumorigenic or anti-tumorigenic activity. The 
cell lines investigated in our studies are derived from tumors of different stages and origin,
and it is therefore conceivable that GDF-15 may regulate in either a positive or negative
* Revision notes
manner, depending on molecular and cellular contexts. Antagonistic effects have also been 
shown for TGF and its effects on different glioma cell lines (see also Jennings et al., 1991).
Although previous studies suggested that GDF-15 can regulate invasiveness in cancer cell 
lines, results of these former studies were based on a single cell line, without comparing the 
results with other cell lines derived from the same cancer types. It has been shown, for 
example, that GDF-15 significantly increases invasiveness of SNU-216, a human gastric 
cancer cell line (Lee et al., 2003). Evidently, this does not prove that all available gastric 
cancer cell lines would respond in the same way. Our study compares GDF-15 dependent 
invasion in 8 different cancer cell lines, which may differ in a variety of subtle respects. 
6. Lastly, no effect on apoptosis was noted. How do the authors explain this result, which is 
different from previously published studies?
Most in vitro studies suggest GDF-15- induces apoptosis in cancer cell lines. However, data 
from the literature provide high expression of GDF-15 in many tumors, a finding that is hard 
to be reconciled with the proposed tumor suppressor activity of GDF-15. Previous studies 
from our laboratory clearly demonstrate that GDF-15 can protect cerebellar granule cells from 
apoptotic cell death in vitro (Subramaniam et al., 2003), i.e. GDF-15 may function as an anti-
apoptotic factor. To our knowledge, none of the previously published studies has shown pro-
apoptotic effects of GDF-15 in glioma cultures.
7. The conclusions of this study are overstated.
Conclusions have been changed 
Reviewer 2
1. How are primary and secondary GBM differentiated (clinically or molecular). 
Primary and secondary GBM were differentiated as described earlier [22] In brief, tumors 
were histopathologically classified according to the classification of the WHO. Tumors were 
characterized as secondary GBM in patients with previous identified low grade (WHO II and 
WHO III) glioblastomas in accordance with Kleihues. 
2. Why was no fresh material used for qPCR?
We have now included fresh material provided by the Molecular Biology Laboratories, 
Department of Neurosurgery, University of Heidelberg. We got 9 frozen tissue samples of
primary GBM and used the samples for qPCR and immunohistochemistry. The results of the 
qPCR with fresh primary GBM confirmed data obtained by IHC (low GDF-15 expression in 8 
out of 9 tumors, (see also the figure on the last page of our response). Three of the primary 
cultures used for qPCR correspond to fresh tissue samples (Tab.1). Since one secondary 
GBM, two anaplastic astrocytoma and one oligodendroblastoma were provided as frozen 
sections on coverslips we could not perform qPCR and used the material directly for 
immunohistochemistry. However, primary cells derived from these tumors revealed high 
amounts of GDF-15 mRNA (Tab.1), although we were not able to show any ir in the 
oligodendroglioma grade III. 
3. What is a low-passage culture and how was the immunohisto / qPCR correlation?
We added a list with tumor number, passage number, sex and age of the total material used in 
this study (Tab. 1).
4. Table 2 should be presented earlier in the results section.
The correlation of p53 and GDF-15 is now mentioned in the Results section.
5. Discussion should be shortened.
We now shortened the discussion.      
This figure shows quantitative PCR of 9 primary tumors
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Table I. Tumor number, passage number of primary cell cultures, sex and age of patients. 
Cell cultures corresponding to tumors used for immunohistochemistry are colour-coded.
primary cultures Passage Sex Age
OGG II
NCH171 5 f 53
NCH177 5 m 39
NCH216 3 m 78
NCH240 3 f 64
NCH362 6 f 27
OGG III
NCH238 3 f 62
NCH273 4 m 67
NCH281 3 f 59
NCH293 4 f 49
NCH345 3 m 43
OAG III
NCH200 4 m 33
NCH248 4 m 27
NCH259 4 f 52
NCH297 2 f 45
NCH349 6 m 38
OAG II
NCH91 13 f 60
NCH180 4 f 49
NCH204 2 m 40
NCH302 2 m 52
NCH327 4 m 42
DAG II
NCH110 13 m 25
NCH169 7 f 28
NCH295 3 m 38
NCH323 3 m 25
NCH353 9 f 38
NCH232 2 m 29
NCH170 3 m 63
NCH159 2 f 34
NCH382 2 m 31
NCH185 3 f 35
AAG III
NCH38 11 m 49
NCH133 8 m 26
NCH158 4 m 65
NCH192 3 f 55
NCH218 3 f 43
NCH389 2 m 65
NCH78 5 m 38
NCH128 5 m 33
NCH326 3 m 31
NCH209 6 f 41
SGG IV
NCH173 3 m 18
NCH193 4 m 45
NCH199 6 m 38
NCH214 4 m 40
NCH246 2 m 38
NCH407 3 f 43
NCH203 4 f 58
NCH198 2 f 27
NCH217 4 m 28
PGG IV
NCH82 27 m 56
NCH89 3 f 41
NCH125 3 m 43
NCH156 6 m 54
NCH149 5 m 64
NCH186 3 f 62
NCH287 2 m 55
NCH210 6 m 60
NCH325 7 m 31





















Table II. Origin and p53 status of the nine human glioblastoma cell lines used in our study. 
cell line origin p53 status
A172 GB wt
D247MG gliosarcoma wt
LN-18 de novo GB mutant / wt
LN-229 de novo GB wt
LN-308 de novo GB null
LN-319 de novo AA mutant
LN-428 de novo GB mutant
U87MG de novo GB wt
U373MG de novo GB mutant
GB: glioblastoma; AA: anaplastic astrocytoma.
Table(2)
Table III. Number of TUNEL-positive cells / 1000 cells in ten glioblastoma cell lines treated 
as indicated. Neither GDF-15 anti-serum nor recombinant human (rh)GDF-15 affect apoptosis 








A172 1 1 <1
D247 1 1 <1
LN-18 1 2 2
LN-229 1 2 1
LN-308 2 3 1
LN-319 4 5 4
LN-428 3 3 2
U87MG 3 4 4
U373MG 4 4 6
Table(3)
